Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05093933 · ClinicalTrials.gov registry record · Phase 3
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 6,106
- Enrollment target
NCT05093933 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 6,106 participants.
The verdict
NCT05093933, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 6,106 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart failure or need for outpatient intravenous (IV) diuretics. The primary hypothesis is that vericiguat is superior to placebo in reducing the risk of cardiovascular death or heart failure hospitalization.
Interventions
- DRUG Placebo
- DRUG Vericiguat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,106 participants |
| Start Date | 2021-11-02 |
| Est. Completion | 2025-02-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05093933
The ClinicalTrials.gov registry entry for NCT05093933 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 6,106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05093933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05093933 about?
NCT05093933 is a clinical study titled "A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)". The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart failure or need for outpatient intra...
What is the current status of trial NCT05093933?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 6,106 participants. The study started on 2021-11-02. Estimated completion is 2025-02-05.
What interventions are being tested in trial NCT05093933?
The interventions under investigation include: Placebo (DRUG), Vericiguat (DRUG).
Who is sponsoring clinical trial NCT05093933?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.